Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide

Melissa A. McDiarmid, Paul Timothy Strickland, Ken Kolodner, John Hansen, David Jacobson-Kram

Research output: Contribution to journalArticle

Abstract

Determinations of baseline sister-chromatid exchanges (SCE) have been used extensively as indicators of previous mutagen exposure in both animals and humans. Hypersensitivity to mutagen-induced SCE levels has also been studied in a variation on the basic technique as an indication of previous mutagen exposure in a stressed or provocative test system. The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients. This study examined the in-vivo genotoxic effects of CP therapy by comparing baseline and phosphoramide mustard (PM)-induced SCEs in therapeutically (in-vivo) treated cancer patients with SCE levels in newly diagnosed, but not treated patients. Therapeutically treated patients showed statistically higher baseline SCE frequencies than untreated control patients with a mean SCE/cell of 6.95 vs. 5.25, p <0.016. When net SCE values (induced minus baseline) were determined in PM-exposed cells in-vitro both at low dose (0.1 μg/ml PM) and high dose (0.25 μg/ml PM) however, the difference was not significant between therapeutically treated and untreated control patients. The return to control SCE levels as a function of time since last therapeutic treatment was also evaluated and no difference was found between the rate of decline of PM-induced SCEs and baseline SCE levels over time.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalMutation Research/Genetic Toxicology
Volume241
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Sister Chromatid Exchange
Cyclophosphamide
Mutagens
Neoplasms
Lymphocytes
Animals
Blood
phosphoramide mustard
Hypersensitivity
Therapeutics
Pharmaceutical Preparations

Keywords

  • Alkylating anti-cancer drugs
  • Baseline SCEs
  • Cyclophosphamide
  • Phosphoramide mustard-induced SCEs

ASJC Scopus subject areas

  • Genetics
  • Toxicology
  • Medicine(all)

Cite this

Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide. / McDiarmid, Melissa A.; Strickland, Paul Timothy; Kolodner, Ken; Hansen, John; Jacobson-Kram, David.

In: Mutation Research/Genetic Toxicology, Vol. 241, No. 3, 1990, p. 273-278.

Research output: Contribution to journalArticle

McDiarmid, Melissa A. ; Strickland, Paul Timothy ; Kolodner, Ken ; Hansen, John ; Jacobson-Kram, David. / Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide. In: Mutation Research/Genetic Toxicology. 1990 ; Vol. 241, No. 3. pp. 273-278.
@article{8d0ec136f784479d83c0bad8e25f046f,
title = "Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide",
abstract = "Determinations of baseline sister-chromatid exchanges (SCE) have been used extensively as indicators of previous mutagen exposure in both animals and humans. Hypersensitivity to mutagen-induced SCE levels has also been studied in a variation on the basic technique as an indication of previous mutagen exposure in a stressed or provocative test system. The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients. This study examined the in-vivo genotoxic effects of CP therapy by comparing baseline and phosphoramide mustard (PM)-induced SCEs in therapeutically (in-vivo) treated cancer patients with SCE levels in newly diagnosed, but not treated patients. Therapeutically treated patients showed statistically higher baseline SCE frequencies than untreated control patients with a mean SCE/cell of 6.95 vs. 5.25, p <0.016. When net SCE values (induced minus baseline) were determined in PM-exposed cells in-vitro both at low dose (0.1 μg/ml PM) and high dose (0.25 μg/ml PM) however, the difference was not significant between therapeutically treated and untreated control patients. The return to control SCE levels as a function of time since last therapeutic treatment was also evaluated and no difference was found between the rate of decline of PM-induced SCEs and baseline SCE levels over time.",
keywords = "Alkylating anti-cancer drugs, Baseline SCEs, Cyclophosphamide, Phosphoramide mustard-induced SCEs",
author = "McDiarmid, {Melissa A.} and Strickland, {Paul Timothy} and Ken Kolodner and John Hansen and David Jacobson-Kram",
year = "1990",
doi = "10.1016/0165-1218(90)90024-V",
language = "English (US)",
volume = "241",
pages = "273--278",
journal = "Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure",
issn = "0165-1218",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide

AU - McDiarmid, Melissa A.

AU - Strickland, Paul Timothy

AU - Kolodner, Ken

AU - Hansen, John

AU - Jacobson-Kram, David

PY - 1990

Y1 - 1990

N2 - Determinations of baseline sister-chromatid exchanges (SCE) have been used extensively as indicators of previous mutagen exposure in both animals and humans. Hypersensitivity to mutagen-induced SCE levels has also been studied in a variation on the basic technique as an indication of previous mutagen exposure in a stressed or provocative test system. The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients. This study examined the in-vivo genotoxic effects of CP therapy by comparing baseline and phosphoramide mustard (PM)-induced SCEs in therapeutically (in-vivo) treated cancer patients with SCE levels in newly diagnosed, but not treated patients. Therapeutically treated patients showed statistically higher baseline SCE frequencies than untreated control patients with a mean SCE/cell of 6.95 vs. 5.25, p <0.016. When net SCE values (induced minus baseline) were determined in PM-exposed cells in-vitro both at low dose (0.1 μg/ml PM) and high dose (0.25 μg/ml PM) however, the difference was not significant between therapeutically treated and untreated control patients. The return to control SCE levels as a function of time since last therapeutic treatment was also evaluated and no difference was found between the rate of decline of PM-induced SCEs and baseline SCE levels over time.

AB - Determinations of baseline sister-chromatid exchanges (SCE) have been used extensively as indicators of previous mutagen exposure in both animals and humans. Hypersensitivity to mutagen-induced SCE levels has also been studied in a variation on the basic technique as an indication of previous mutagen exposure in a stressed or provocative test system. The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients. This study examined the in-vivo genotoxic effects of CP therapy by comparing baseline and phosphoramide mustard (PM)-induced SCEs in therapeutically (in-vivo) treated cancer patients with SCE levels in newly diagnosed, but not treated patients. Therapeutically treated patients showed statistically higher baseline SCE frequencies than untreated control patients with a mean SCE/cell of 6.95 vs. 5.25, p <0.016. When net SCE values (induced minus baseline) were determined in PM-exposed cells in-vitro both at low dose (0.1 μg/ml PM) and high dose (0.25 μg/ml PM) however, the difference was not significant between therapeutically treated and untreated control patients. The return to control SCE levels as a function of time since last therapeutic treatment was also evaluated and no difference was found between the rate of decline of PM-induced SCEs and baseline SCE levels over time.

KW - Alkylating anti-cancer drugs

KW - Baseline SCEs

KW - Cyclophosphamide

KW - Phosphoramide mustard-induced SCEs

UR - http://www.scopus.com/inward/record.url?scp=0025332746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025332746&partnerID=8YFLogxK

U2 - 10.1016/0165-1218(90)90024-V

DO - 10.1016/0165-1218(90)90024-V

M3 - Article

C2 - 2366806

AN - SCOPUS:0025332746

VL - 241

SP - 273

EP - 278

JO - Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure

JF - Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure

SN - 0165-1218

IS - 3

ER -